Cancer care group Helsinn has put $50m into a corporate venturing unit called Helsinn Investment Fund that will target early-stage companies.

The upscale bedding provider took its total funding to more than $22m with $18.3m in series B funding from investors including Channel 4's Commercial Growth Fund.

Crispr Therapeutics, a gene editing drug developer backed by Bayer, Vertex, Celgene and GlaxoSmithKline, has set the terms for an offering on Nasdaq.

Minima is based on technology, which which makes digital computing as much as 20-times more energy efficient than current technology, spun out from VTT Technical Research Centre of Finland, Aalto University and the University of Turku.

The internet-of-things network developer is aiming for between $100m and $200m at a $600m valuation, with an unnamed Chinese strategic investor set to take part.

The bank led screen sharing technology developer Vizolution's latest round, which will support international growth and product development.

Venture firm Medicxi is investing $11.2m in Kymo Therapeutics, a startup launched by biotech company Metabrain Research to advance its kynurenine metabolism inhibitor research.

Financial risk mitigation firm Icap, which led OpenGamma's $15m series C round in 2012, returned to co-lead a $13.3m round with fellow existing investor Accel.